Vera Therapeutics, Inc.(VERA) Stock Research - Grey Stern Research

Vera Therapeutics, Inc. (VERA) Stock Analysis

$36.70 (-0.38%)

VERA Financial Performance


Use the table below to view Vera Therapeutics, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2024

Metric Value Ranking among Peers
Price $36.70 -
52 Week Low $9.24 -
52 Week High $50.78 -
Market Cap $2.0 Billion 3/18
Gross Margin 0% 5/18
Profit Margin 0% 1/18
EBITDA margin -100% 2/18
Q1 - 2024 Revenue $0 7/18
Q1 - 2024 Earnings -$28.4 Million 8/18
Q1 - 2024 Free Cash Flow -$33.8 Million 11/18
Trailing 4 Quarters Revenue $0 8/18
Trailing 4 Quarters Earnings -$94.3 Million 8/18
Quarterly Earnings Growth 5% 6/18
Annual Earnings Growth 26% 7/18
Quarterly Revenue Growth 0% 4/18
Annual Revenue Growth 0% 4/18
Cash On Hand $69.1 Million 9/18
Short Term Debt $2.3 Million 7/18
Long Term Debt $50.1 Million 4/18

Vera Therapeutics, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Vera Therapeutics, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 2/18
PS -1.00 8/18
PB 5.68 5/18
PC 29.05 4/18
Liabilities to Equity 0.19 9/18
ROA -0.22 5/18
ROE -0.27 6/18
Current Ratio 6.37 8/18
Quick Ratio 6.13 8/18
Long Term Debt to Equity 0.14 5/18
Debt to Equity 0.15 6/18
Burn Rate 2.23 10/18
Cash to Cap 0.03 15/18
CCR 1.19 6/18
EV to EBITDA -1.00 1/18
EV to Revenue -1.00 8/18

Company Details

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

CEO: Dr. Marshall Fordyce M.D.

Website: https://veratx.com

Address: 170 Harbor Way South San Francisco, CA

Exchange: NASDAQ Global Market

Industry: Biotechnology

Vera Therapeutics, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Vera Therapeutics, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
AnaptysBio, Inc. ANAB $1.0 Billion
Cogent Biosciences, Inc. COGT $910.2 Million
Cytokinetics, Incorporated CYTK $7.0 Billion
Aldeyra Therapeutics, Inc. ALDX $246.6 Million
Eton Pharmaceuticals, Inc. ETON $92.0 Million
RAPT Therapeutics, Inc. RAPT $116.6 Million
Tarsus Pharmaceuticals, Inc. TARS $944.9 Million
Edgewise Therapeutics, Inc. EWTX $1.8 Billion
Monte Rosa Therapeutics, Inc. GLUE $285.6 Million
Travere Therapeutics, Inc. TVTX $752.9 Million
DICE Therapeutics, Inc. DICE $2.3 Billion
Tyra Biosciences, Inc. TYRA $1.1 Billion
Rallybio Corporation RLYB $56.4 Million
Anebulo Pharmaceuticals, Inc. ANEB $57.1 Million
Xilio Therapeutics, Inc. XLO $37.3 Million
Ventyx Biosciences, Inc. VTYX $208.0 Million
LianBio LIAN $34.5 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
VERA Income Statements
Quarter Year Revenue Earnings
Q1 2024 $ 0 -$28.4 Million
Q4 2023 $ 0 -$25.7 Million
Q3 2023 $ 0 -$20.1 Million
Q2 2023 $ 0 -$20.2 Million
Q1 2023 $ 0 -$29.8 Million
Q4 2022 $ 0 -$32.4 Million
Q3 2022 $ 0 -$24.7 Million
Q2 2022 $ 0 -$14.9 Million

View All

VERA Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q1 2024 $69.1 Million $419.4 Million $53.3 Million $353.5 Million
Q4 2023 $160.7 Million $175.5 Million $53.7 Million $101.7 Million
Q3 2023 $27.4 Million $175.6 Million $29.5 Million $123.7 Million
Q2 2023 $33.9 Million $195.2 Million $30.1 Million $140.5 Million
Q1 2023 $137.4 Million $209.6 Million $30.7 Million $157.7 Million
Q4 2022 $43.5 Million $131.4 Million $31.3 Million $76.9 Million
Q3 2022 $30.5 Million $131.4 Million $12.1 Million $105.7 Million
Q2 2022 $50.4 Million $148.8 Million $12.2 Million $121.5 Million

View All

VERA Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2024 -$33.8 Million $0 $23.4 Million
Q4 2023 -$25.2 Million -$63,000 $18.2 Million
Q3 2023 -$23.0 Million $0 -$6.4 Million
Q2 2023 -$17.8 Million $0 -$103.8 Million
Q1 2023 -$26.3 Million $0 $93.9 Million
Q4 2022 -$21.2 Million -$6,000 $13.0 Million
Q3 2022 -$27.5 Million -$56,000 -$20.0 Million
Q2 2022 -$19.0 Million -$6,000 -$61.1 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions